Categories: Top News

CVRx to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call on January 25th, 2024

MINNEAPOLIS, Jan. 11, 2024 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2023 financial and operating results after market close on Thursday, January 25th, 2024. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.

A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time.

About CVRx, Inc.

CVRx is a commercial-stage medical device company focused on the developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com

Media Contact:
Laura O’Neill
Finn Partners
212-867-1762
laura.oneill@finnpartners.com

GlobeNewswire

GlobeNewswire, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Recent Posts

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zynex, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZYXI

NEW YORK, April 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights…

9 hours ago

Writer/painter-turned cultural heritage preserver behind Spring Festival’s UNESCO heritage status success

Global Times: Feng Jicai leads efforts to preserve China's cultural heritage through art, literature, and…

10 hours ago

Boston Hemp Launches New Line of Premium THCa Concentrates

Hanover, MA , April 20, 2025 (GLOBE NEWSWIRE) -- Boston Hemp Inc., a leader in…

10 hours ago

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Bakkt Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BKKT

NEW YORK, April 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights…

11 hours ago

Australian Dollar Speculative Net Positions Improve, But Remain in the Negative

The latest data release from the Commodity Futures Trading Commission (CFTC) reveals a marginal improvement…

17 hours ago

This website uses cookies.